RemeGen Reports the Result of Disitamab Vedotin (RC48) in the P-II trial for the Treatment of Urothelial Carcinoma
Shots:
- Both the P-II study (NCT03507166) evalutes safety & efficacy of disitamab vedotin (2 mg/kg IV; Q2W) HER2-positive previously treated advanced urothelial carcinoma (UC) patients (n=107)
- The results of the 1EP study showed an ORR of 50.5% assessed by a BIRC, with consistent results in subgroups, incl. patients with liver metastasis & those previously treated with anti–PD-1/L1 therapies. As of May 10, 2022, the mDoR was 7.3 mos., while median PFS & OS were 5.9 & 14.2 mos., respectively
- Disitamab Vedotin (RC48) has received market approval in China & was granted conditional marketing approval in June’21 by the NMPA. These two studies' combined analysis was published in the JCO
Ref: PR Newswire | Image: RemeGen
Related News:- Seagen Signs an Exclusive WW License Agreement with RemeGen to Develop and Commercialize Disitamab Vedotin
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
